Image guided drug delivery has gained significant attention during the last few years. Labelling nanoparticles or macromolecules and monitoring their fate in the body provides information that can be used to modulate their biodistribution and improve their pharmacokinetics. In this study we label antibodies and monitor their distribution in the tumours post intravenous injection. Using Focused Ultrasound (FUS, a non-invasive method of hyperthermia) we increase the tumour temperature to 42°C for a short period of time (3-5 min) and we observe an increased accumulation of labelled antibody. Repetition of focused ultrasound induced hyperthermic treatment increased still further the accumulation of the antibodies in the tumour. This treatment also augmented the accumulation of other macromolecules nonspecific in the tumour, such as IgG and albumin. These effects may be used to enhance the therapeutic efficiency of antibodies and/or targeted nanoparticles.
Introduction
Theranostic agents are diverse in nature, from single molecules to large complexes and nanoparticles which have the functions of diagnosis and treatment [1] . Theranostic agents are labelled with one or more probes (multimodal imaging), allowing real-time imaging of the therapeutic by a number of imaging modes such as MRI, PET, ultrasound or optical imaging [2] [3] [4] .
Theranostic Nanoparticles have gained significant attention due to their properties and characteristic advantages for their use in cancer. Nano-theranostics have raised hopes for treating cancer using imaging and therapy combined in one nanoparticle [5] .
The data derived from imaging using theranostics provide information for a) drug biodistribution, b) monitoring of the therapeutic effect e.g. diminishing of tumour growth, c) interactions of the drug with receptors, d) mechanisms of action, and e) metabolism & clearance. Overall, theranostics provide information how the in vivo biodistribution and clearance of the potential therapeutic agent develop. This in turn allows adjustment of treatment parameters (e.g. dosage, timings) to best enhance the therapeutic effects [6] .
Labelled antibodies are an important group of theranostics as they can provide insight on the cancer target expression levels [7, 8] . Labelled antibodies have been suggested for detecting and treating breast cancer [9] .
Multifunctional nanoparticles that label tumours for additional imaging have been increasingly introduced in the field of oncology research [10] . These nanoparticles are usually coupled with targeting ligands such as antibodies for cancer biomarker targeting [11] .
Therapeutic nanoparticles are coupled to antibodies for specific deliver of their cargo to disease cells [12] . Recently antibodies and or their versions are suggested for coupling on a variety of theranostic nanoparticles for better specificity and precision medicine [13] [14] [15] .
Antibodies including Her-2 antibody coupled with radiolabels, MRI labels and or fluorescent labels have been suggested as theranostics [16] [17] [18] .
Focused Ultrasound mediated drug delivery has recently raised great interest [19, 20] . The method is suited to enhancing the delivery of nanoparticles in tumours for triggered release and targeted drug delivery [21] . It also allows for thermally sensitive liposomal drug delivery, enhancing delivery through sonoporation as well as improving drug delivery to the brain [20] .
Along with chemotherapy, hyperthermia has experienced the development of techniques as safe and effective to treat certain forms of cancer [22] . In particular, the use of High Intensity Focused Ultrasound (HIFU or FUS) allows the non-invasive heating of internal tissue areas to coagulation temperatures, effectively destroying targeted tumour tissue [23, 24] . Lower power settings may also be used to induce sub-lethal (normally < 43 o C), highly localised hyperthermia that does not damage tissues directly. There have been a number of recent reports discussing the effects of such mild hyperthermia on blood irrigation and the enhanced uptake of therapeutic agents [25] . The combination of mild hyperthermia and thermoresponsive chemotherapy agents has also emerged as a recent development in Thermodox clinical phase III [26] .
The method of focused ultrasound mediated hyperthermia drug delivery has been harnessed for other carriers or macromolecules however to a much lesser extent. In a recent study, it has been used to deliver B3 mAb antibody in axenograft murine cancer model, suggesting that this method could be developed for the delivery of radio-immunotherapy in tumours [27] . Recently Cetuximab was also delivered in mice in a similar fashion, showing an improvement on anti-tumour effect [28] .
Trastuzumab is a monoclonal antibody that binds to HER2/neu receptors, blocking human Epidermal Growth Factor Receptor 2 (HER-2) downstream signalling and inhibiting cancer cells proliferation. The HER2 gene encodes a transmembrane tyrosine kinase receptor that belongs to the Epidermal Growth Factor Receptor (EGFR) family. This family of receptors includes four members (EGFR/HER1, HER2, HER3 and HER4) that function by stimulating growth factor signalling pathways [29, 30] . In 1998, Trastuzumab, under the brandname Herceptin ®, received FDA approval for the treatment of breast cancer [31] . At the same time FDA approved HercepTest (Dako, Denmark) for diagnosis of HER2 expression [31, 32] .
Preclinical and clinical studies have clearly demonstrated that the combination of Trastuzumab with small molecule chemotherapeutics (e.g. emtasine Kadcyla®, antibody drug conjugates) significantly prolongs the survival of patients with HER2-positive metastatic breast cancer [33] . In a very recent study lapatinib, a tyrosine kinase inhibitor in clinical development for cancer and a potent dual inhibitor of Epidermal Growth Factor Receptor was combined with Trastuzumab showing impressive effects on the disease free survival parameter of patients that underwent the treatment [34] .
Since 2005, significant work has been done in the area of imaging, also including Trastuzumab as targeting molecule [35] . Dual labelled fluorescence and radio-labeled Trastuzumab has been tested to diagnose tumours in mice [36] [37] [38] . Labelling of Trastuzumab for MRI has been proved more challenging and more sophisticated approaches have been introduced [39] .
With the aim to understand the potential effect of hyperthermia on antibody targeted theranostics (including nanotheranostics) this study investigates the biodistribution of labelled antibody in the tumour with and without Focused Ultrasound treatment. In this work, we report on the effects of FUS-induced mild hyperthermia on the uptake of Trastuzumab to murine xenograft tumours. The localisation of the antibodies (with a covalently attached dye) was tracked using a Near Infrared Fluorescence (NIRF) imaging system.
Materials and Methods
Unless otherwise stated, Trastuzumab/Herceptin was from Genentech (San Francisco CA, USA), XenoLight CF 750 NIRF dye and electrophoresis reagents from Perkin Elmer (Waltham MA, USA), buffers and cell reagents from GE Healthcare (UK) while other chemicals were from Sigma Aldrich (St. Louis MI, USA).
XL750-Trastuzumab conjugation
Trastuzumab (0.5 mL, 21 mg/mL) was buffer exchanged using a PD-10 column to Dulbecco's phosphate buffered saline (DPBS) with pH adjusted to 8.3 with redistilled triethylamine. Samples of the labelled antibody were analysed by SDS-PAGE using 4-20 % tris-glycine nonreducing gels and highlighting protein bands with silver stain (SilverQuest, Sigma Aldrich). No significant differences were seen before and after incubation for 7 min at 42 o C, suggesting that the antibody should be stable to mild hyperthermia.
Cell culture and tumor generation
IGROV-1 (ovarian cancer moderately expressing Her-2 receptor), SKOV-3 (ovarian cancer highly expressing Her-2 receptor) and BT474 (breast cancer highly expressing Her-2 receptor) cells were routinely cultured in medium supplemented with fetal calf serum 10 % v/v. When cells reached 80-90 % confluence, they were harvested and prepared for implantation in mice.
Post harvesting, cells were washed in saline and counted using a haemocytometer.
Accordingly with the cell counting an equal volume of saline containing the cells was mixed with matrigel (Geltrex, Gibco). For the tumor generation, 5x 10 6 cells contained in 50 % matrigel mixture were inoculated subcutaneously on both flanks of 8 weeks old SHO mice (Charles River, Germany). After about 2 weeks, the formed tumours on each flank had reached an average diameter of 5-6 mm. All experiments were approved by the Home office UK. Imaging and treatments were performed in n=3 animals per group.
FUS-induced hyperthermia
Mice were treated with FUS-induced hyperthermia using a Therapy and Imaging Probe System (TIPS, Philips Research, Briarcliff NY, USA). Under isoflurane anesthesia they were placed on a warmed gel pad over an ultrasound absorbing mat. Two or three fine-wire 
Near Infrared Fluorescence Imaging
The tumour bearing mice were injected intravenously with XL750-Trastuzumab (200 µL of 1 mg/mL; ~ 8 mg/kg mouse body weight) in sterile mM HEPES pH 7.4 with 5% glucose (w/v).
The injections were performed with anaesthetized mice using a syringe driver connected to a cannula inserted in the tail vein. The injection rate used was 400 µL/min. immediately post injection, each anaesthetised animal was placed into the Maestro EX (Perkin Elmer) for 
3.Results
The combination of a small animal FUS guided by real-time temperature measurements from implanted thermocouples allows the application of localised and repeatable hyperthermia without deviations from the target temperature (see Figure 1 ). In turn, NIRF imaging allows us to monitor the resulting changes in distribution and tumour uptake of a labelled material in real-time. Other methods of preclinical imaging such as MRI and PET (SPECT/CT) suffer from significantly longer setup and image acquisition times although resolution is substantially better [40] . The TIPS/NIRF combination we designed in our study allows the imaging of drug biodistribution 1-2 minutes after insonation and repeated imaging at ~ 2 min intervals following, for periods of several hours because the animal is allowed to regain consciousness [41] . This gives greater confidence in the drug biodistribution behaviours that are imaged.
NIRF optical imaging is non-hazardous (no radioactivity) preclinical and enables the tracking of the NIRF signal to ~ 1 cm deep inside the mouse body with high sensitivity. The short depth of the signal detection can be circumvented by rotating the mouse from ventral to dorsal position to provide information of the labelled drug accumulation in the RES (reticulo endothelial system, in particular liver and spleen) organs of the animal [42] . In our study we used NIRF imaging to detect the distribution of labelled Trastuzumab in the tumour (see supplementary video).
Effect of focused ultrasound treatment on labelled antibody biodistribution and tumoural uptake
Trastuzumab biodistribution was first studied without hyperthermia treatment. In Figure Figure S2 ). On the ventral side, fluorescence accumulated principally in the liver and the bladder over the same period, as the consequence of kidney clearance previously described (Supplementary material Figure S3 ).
The effects of the application of FUS-induced mild hyperthermia on tumoural uptake were then examined (figure 2, middle panel). The temperature was monitored using thermocouples ( Figure S5 ).The selected hyperthermia regimen was 41 o C for 5 min (this is brief compared to other Focused Ultrasound hyperthermia studies recently reviewed [43] ).
The change in apparent tumour uptake was noticed within 4 h, with a significant accumulation of NIRF signal in the treated by FUS area. But when the tumour was excised, only a small increase in accumulation was observed.
In order to improve the uptake, we repeated the FUS treatment at different time intervals post injection (see Figure 2 This might be due to the fact that tumour excision was immediate after application of hyperthermia indicating that the signal coming from the tumour on the living animal is from the blood vessels and tissues surrounding the tumour. This effect from hyperthermia application was reported by Khaibullina et al. who also described a large accumulation of the antibodies in the surrounding muscle and skin [44] .
However the effect was evident when FUS-induced hyperthermia was repeated twice or thrice at different time points. The benefit of the use of FUS to improve the uptake of antibody therapeutics was already demonstrated [27] but in our study we observed a clear response in the antibody uptake upon repetition of thermal dosing that is dependent the number of repetition of FUS applications.
The NIRF signal coming from the label that is attached to Trastuzumab appeared to be retained in the tumours for several days either without or with FUS treatment (supplementary figures Fig S2 and Fig S4) . This might be coming from Trastuzumab as the antibody has a very long half-life (28 days) [45] . Whether NIRF dye stays attached to the antibodies or not distributed in the tumours remains to be investigated. It is however likely that the signal comes from the antibody-label conjugate as the small NIRF molecule clears out of the animal.
We also observed that the intensity of the signal appeared to be strong for at least 7 days (see Supp. Material Figures S2 and S4) . In a recent study the biological properties of Trastuzumab were not affected after the application of the effect of hyperthermia [46] .
NIRF signal assessment in FUS treated tumours versus non treated tumours
As expected, without FUS treatment, the antibody uptake appeared to be the same in both tumours having similar sizes and development, and possibly the same vascularisation.
In Figure 4 , we quantify the NIRF brightness from area matched regions (e.g. centre of the tumour) of left and right hand tumours, compared to a shoulder muscle considered as control.
In Figure 4 , we quantify the NIRF brightness from area matched regions (e.g. centre of the tumour) of left and right hand tumours, in the absence of FUS, or in the presence of 1 or 3 rounds of FUS, in order to confirm the effect of treatment on tumour accumulation.
Conscientious of the nature of the NIRF signal and the problems that arise from its absolute quantification, we propose here a relative way to assess the magnitude of the physiological events observed so far, using shoulder muscle brightness as control.
When the fluorescent antibody was injected it was distributed to the two tumours to the same extent (Figure 4a and 4b) . Without FUS treatment uptake appeared to be the same in presented clearly an increase of 2-3 fold (Figure 4c ) in NIRF signal intensity. After 3 rounds of FUS treatment the gain in NIRF signal was estimated to be 3-4 fold ( figure 4d ) . This method of assessment is considering the intensity of the signal and not the total phenomenon e.g.
AUC of signal intensity versus time.
We performed the same quantification on tumours excised from mice, sacrificed at 5 h post treatment with 3xFUS immediately after the application of the last FUS hyperthermia ( Figure   5 ). Figure 5c presents the NIRF signal analysis derived from the excised tumours coming from a small matched region (e.g. centre of the tumour), indicating that for that area a 2-fold increase in NIRF-antibody signal. These results demonstrate that 3 rounds of mild hyperthermia accelerate and increase the tumoral uptake of the antibody therefore changing the pharmacokinetics of the therapy. The tumours were excised immediately after the application of the last FUS induced hyperthermia.
Uptake comparison between several proteins and tumour models
In order to better understand the phenomenon of tumoral uptake induced by hyperthermia, two NIRF labelled non-tumour specific proteins: IgG and albumin, were also tested in mice 
Discussion
In this study we investigated the effect of focused ultrasound induced hyperthermia on Trastuzumab concentration in the tumour after intravenous administration in xenograft mice.
The application of mild hyperthermia offers the possibility to accelerate and increase the accumulation in the tumours of Trastuzumab antibody in agreement with previous study [44] .
In the study presented by Khaibullina et al. and Wang et al hyperthermia was applied for 8-15 min and only once [27, 44] . In our studies the repetition of mild hyperthermia induced by FUS appears to have an additive effect on the uptake of the macromolecule by the tumour.
Our results indicate that the hyperthermia effect on the tumour and its increased extravasation is independent on the specificity of the macromolecule to a receptor 
Conclusion
In this study we have shown that FUS-induced short duration hyperthermia applied noninvasively and locally in the tumour can increase the accumulation of macromolecular drugs such as antibodies specifically in the tumours. The effect is dependent on the repetition of focused ultrasound treatments. 
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